Company intelligence / Profile preview

ALIÓN

Menlo Park, California, United Statestemposvegasicilia.com ↗

Ownership: Private
Employees: ~49
Development stage: Commercial

Overview

Alion Pharmaceuticals develops small molecule therapeutics for central nervous system diseases, focusing on modulating protein-protein interactions and ion channels. The company uses proprietary computational chemistry to accelerate early-stage drug discovery. Recent collaborations have validated activity of several compounds against targets relevant to Alzheimer’s disease, but there is no public evidence of clinical trial results or advanced-stage programs as of March 2025

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

LamdaGen Corporation (collaboration on drug discovery technologies)Aurora Biomed Inc. and Specs (Ion Channel Consortium partnership)

Beyond the preview

Go deeper on ALIÓN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALIÓN.

Explore the full profile